guest ::
| Home > Publications Database > The diagnostic value of transcranial sonography in Swedish parkinsonism patients: A retrospective cohort study with long-term follow-up. > print |
| Home > Publications Database > The diagnostic value of transcranial sonography in Swedish parkinsonism patients: A retrospective cohort study with long-term follow-up. > print |
| 001 | 283119 | ||
| 005 | 20260217130933.0 | ||
| 024 | 7 | _ | |2 doi |a 10.1016/j.prdoa.2025.100411 |
| 024 | 7 | _ | |2 pmid |a pmid:41479687 |
| 024 | 7 | _ | |2 pmc |a pmc:PMC12754217 |
| 037 | _ | _ | |a DZNE-2026-00015 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Stiehm, M. |b 0 |
| 245 | _ | _ | |a The diagnostic value of transcranial sonography in Swedish parkinsonism patients: A retrospective cohort study with long-term follow-up. |
| 260 | _ | _ | |a Amsterdam |b Elsevier |c 2025 |
| 336 | 7 | _ | |2 DRIVER |a article |
| 336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
| 336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |b journal |m journal |s 1767362363_32513 |
| 336 | 7 | _ | |2 BibTeX |a ARTICLE |
| 336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
| 336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
| 520 | _ | _ | |a Although transcranial sonography (TCS) assessing hyperechogenic substantia nigra (SN+) as biomarker for Parkinsońs disease (PD) has been introduced elsewhere, the clinical relevance and accuracy in a Swedish population is still unknown.This retrospective single-center study included 74 patients with predominantly early-stage parkinsonism at first visit who had been examined by TCS from 2013 to 2017 to determine the SN+ biomarker status in relation to PD, atypical parkinsonian disorders (APS), essential tremor (ET) and vascular/secondary/ unspecified parkinsonism, with the aim of long-term follow-up to confirm the clinical diagnosis. The cut-off value for SN+ was regarded as the 90 % percentile of SN echogenicity in a local healthy cohort (here, 0.23 cm2).In 2024, the mean follow-up time was 95 months. Three patients (4 %) without transcranial bone were excluded. SN+ was found in 38/51 patients with finally diagnosed PD and 4/20 patients with other final clinical diagnoses (p < 0.001). Sensitivity was moderate (75 %) whereas specificity and the positive predictive value were higher (80 % and 90 %, respectively). SN area measurements (most abnormal side) were significantly different in PD-patients compared to non-PD patients (n = 63; 0.28 ± 0.09 [95 % CI: 0.25-0.30] cm2 vs. 0.23 ± 0.10 [0.18-0.29] cm2, p 0.035).After a follow-up of up to 8 years, to maximize diagnostic certainty, our findings support the use of TCS as a valuable add-on tool in PD diagnostics in a Swedish patient population, already in the early stage of disease but not for screening. |
| 536 | _ | _ | |0 G:(DE-HGF)POF4-353 |a 353 - Clinical and Health Care Research (POF4-353) |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |2 Other |a Essential tremor |
| 650 | _ | 7 | |2 Other |a Hyperechogenicity |
| 650 | _ | 7 | |2 Other |a Movement disorders |
| 650 | _ | 7 | |2 Other |a Parkinsonism |
| 650 | _ | 7 | |2 Other |a Parkinsońs disease |
| 650 | _ | 7 | |2 Other |a Substantia nigra |
| 650 | _ | 7 | |2 Other |a Transcranial sonography |
| 650 | _ | 7 | |2 Other |a Ultrasound |
| 700 | 1 | _ | |a Nilsson, C. |b 1 |
| 700 | 1 | _ | |a Skogar, Ö |b 2 |
| 700 | 1 | _ | |0 P:(DE-2719)9000336 |a Walter, U. |b 3 |e Last author |u dzne |
| 773 | _ | _ | |0 PERI:(DE-600)3003034-1 |a 10.1016/j.prdoa.2025.100411 |g Vol. 13, p. 100411 - |p 100411 |t Clinical parkinsonism & related disorders |v 13 |x 2590-1125 |y 2025 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/283119/files/DZNE-2026-00015.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://pub.dzne.de/record/283119/files/DZNE-2026-00015.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:283119 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |0 I:(DE-588)1065079516 |6 P:(DE-2719)9000336 |a Deutsches Zentrum für Neurodegenerative Erkrankungen |b 3 |k DZNE |
| 913 | 1 | _ | |0 G:(DE-HGF)POF4-353 |1 G:(DE-HGF)POF4-350 |2 G:(DE-HGF)POF4-300 |3 G:(DE-HGF)POF4 |4 G:(DE-HGF)POF |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0200 |2 StatID |a DBCoverage |b SCOPUS |d 2024-12-18 |
| 915 | _ | _ | |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |a Creative Commons Attribution CC BY 4.0 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0112 |2 StatID |a WoS |b Emerging Sources Citation Index |d 2024-12-18 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0501 |2 StatID |a DBCoverage |b DOAJ Seal |d 2023-05-02T08:53:37Z |
| 915 | _ | _ | |0 StatID:(DE-HGF)0500 |2 StatID |a DBCoverage |b DOAJ |d 2023-05-02T08:53:37Z |
| 915 | _ | _ | |0 StatID:(DE-HGF)0700 |2 StatID |a Fees |d 2024-12-18 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0150 |2 StatID |a DBCoverage |b Web of Science Core Collection |d 2024-12-18 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0510 |2 StatID |a OpenAccess |
| 915 | _ | _ | |0 StatID:(DE-HGF)0030 |2 StatID |a Peer Review |b DOAJ : Anonymous peer review |d 2023-05-02T08:53:37Z |
| 915 | _ | _ | |0 StatID:(DE-HGF)0561 |2 StatID |a Article Processing Charges |d 2024-12-18 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0300 |2 StatID |a DBCoverage |b Medline |d 2024-12-18 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0199 |2 StatID |a DBCoverage |b Clarivate Analytics Master Journal List |d 2024-12-18 |
| 920 | 1 | _ | |0 I:(DE-2719)5000014 |k AG Storch |l Non-Motor Symptoms in Parkinson's disease |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)5000014 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|